The month of June is set to be a crucial period for Unicycive Therapeutics Inc. (UNCY), as it stands on the threshold of a key regulatory event that could significantly shape its near-term prospects.
The FDA decision on the company's lead drug candidate, Oxylanthanum Carbonate, or OLC in short, proposed for the treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis, is due on June 29, 2026.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
by Prabha Kurup
For comments and feedback: contact editorial@rttnews.com